Onyx Biotec Valuation

Is ONYX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ONYX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ONYX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ONYX's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ONYX?

Key metric: As ONYX is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ONYX. This is calculated by dividing ONYX's market cap by their current earnings.
What is ONYX's PE Ratio?
PE Ratio	32x
Earnings	₹30.32m
Market Cap	₹1.02b

ONYX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.5x
Enterprise Value/EBITDA	16x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does ONYX's PE Ratio compare to its peers?

The above table shows the PE ratio for ONYX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	60.6x
506919 Makers Laboratories	20.4x	n/a	₹1.0b
524396 Biofil Chemicals and Pharmaceuticals	191.4x	n/a	₹1.0b
524652 Ind-Swift	2.1x	n/a	₹1.1b
538964 Mercury Laboratories	28.7x	n/a	₹1.1b
ONYX Onyx Biotec	32x	n/a	₹1.0b

Price-To-Earnings vs Peers: ONYX is good value based on its Price-To-Earnings Ratio (32x) compared to the peer average (60.6x).

Price to Earnings Ratio vs Industry

How does ONYX's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap
INDSWFTLAB Ind-Swift Laboratories	1.5x	n/a	US$66.24m
524652 Ind-Swift	2.1x	n/a	US$13.36m

No more companies available in this PE range

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: ONYX is good value based on its Price-To-Earnings Ratio (32x) compared to the Indian Pharmaceuticals industry average (33.7x).

Price to Earnings Ratio vs Fair Ratio

What is ONYX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ONYX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	32x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate ONYX's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Vivimed Labs

₹410.4m

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.

VIVIMEDLAB

₹4.95

-45.9%

Sanofi India

₹142.5b

Manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally.

SANOFI

₹6,197.45

0.8%

-23.0%

Novartis India

₹26.1b

Operates as a healthcare company in India.

500672

₹1,058.30

3.5%

52.4%